Stay updated on Pembrolizumab in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
- Check19 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.9%
- Check26 days agoChange DetectedThe web page has been updated with new study results regarding the efficacy of Pembrolizumab in treating metastatic IBC or non-IBC TNBC, including specific metrics like disease control rate and overall survival timelines. Additionally, there are new reporting dates for results and a focus on biomarker analysis.SummaryDifference20%
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.9%
- Check47 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Breast Cancer Clinical Trial page.